Zai Lab (ZLAB) Debt Ratio (2018 - 2026)

Zai Lab (ZLAB) posted Debt Ratio of 0.2 for Q1 2026, up 11.85% sequentially from 0.17 in Q4 2025, and up 32.04% YoY from 0.15 in Q1 2025.

Zai Lab (ZLAB) Debt Ratio (2018 - 2026) Analysis & Trends

Zai Lab has reported Debt Ratio for 6 years, with the latest figure at 0.2 in Q1 2026.

Quarterly Debt Ratio rose 32.04% year-over-year to 0.2 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.2 (up 32.04% YoY) and the FY2025 annual result came in at 0.17, up 57.06% from the prior year.
Debt Ratio improved to 0.2 in Q1 2026 per ZLAB's latest filing, from 0.17 in the prior quarter.
Over five years, Debt Ratio peaked at 0.2 in Q1 2026 and troughed at 0.05 in Q1 2024.
A 3-year average of 0.13 and a median of 0.15 in 2025 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2025 and 2026: Debt Ratio surged 202.61% in 2025, then soared 32.04% in 2026.
Over 3 years, Debt Ratio stood at 0.11 in 2024, then soared by 57.06% to 0.17 in 2025, then climbed by 11.85% to 0.2 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.2, 0.17, and 0.18 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	Zai Lab	2.91 Bn	2.20 Bn	58.15 Mn	0.22

Download Data